The complex genetics of epigenetics in urothelial carcinomas

Nature Reviews Urology, Published online: 09 October 2020; doi:10.1038/s41585-020-00386-5Cancer sequencing studies have revealed that urothelial carcinomas harbour recurrent mutations in multiple genes that control epigenetics. A major challenge for basic and clinical researchers is to convert this genetic information into biological and pathological insights, as well as to tailor novel therapeutic modalities for individual patients with bladder cancer.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

(American Association for Cancer Research) Analysis of DNA copy number variants (CNVs) in the cells exfoliated in urine showed better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conditions:   Metastatic Bladder Urothelial Carcinoma;   Refractory Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Drug: Docetaxel;   Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Bladder Cancer;   Urothelial Carcinoma Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Bladder Urothelial Carcinoma;   Refractory Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Drug: Docetaxel;   Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Bladder Cancer Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: LINC00460 promoted bladder carcinoma progression via sponging miR-162 to facilitate FOXK1 expression, suggesting that LINC00460 might have the potential of being explored as a therapeutic target for treatment of bladder carcinoma.Pharmacology
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research
an-Cheng Huang Chun-Li Su Analysis of various public databases revealed that HRAS gene mutation frequency and mRNA expression are higher in bladder urothelial carcinoma. Further analysis revealed the roles of oncogenic HRAS, autophagy, and cell senescence signaling in bladder cancer cells sensitized to the anticancer drug cisplatin using the phytochemical pterostilbene. A T24 cell line with the oncogenic HRAS was chosen for further experiments. Indeed, coadministration of pterostilbene increased stronger cytotoxicity on T24 cells compared to HRAS wild-type E7 cells, which was paralleled by neither elevated apoptosis ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We report the ESTRO-ACROP (European Society for Radiotherapy and Oncology - Advisory Committee on Radiation Oncology Practice) recommendations for performing IORT in primary locally advanced rectal cancer. PMID: 33005755 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Radiat Oncol Source Type: research
nández-Gómez JM Abstract The treatment of choice for high-risk non-muscle invasive bladder cancer (NMIBC) is bacillus Calmette-Guérin (BCG). However, when this fails, the indicated treatment is radical cystectomy. In recent years, trials are being developed with various drugs to avoid this surgery in patients with BCG failure. The aim of this article is to update the treatments under study for bladder preservation in this patient population. Non-systematic review, searching PubMed with the terms "Bladder cancer", "Non-muscle invasive bladder cancer", "NMIBC", &quo...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Tags: Actas Urol Esp Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Genetics | Study | Urology & Nephrology